John Tesh has outlived his prognosis by nearly eight years after doctors told him in 2015 he had only 18 months to live, Page Six reports. The former “Entertainment Tonight” co-host told reporters in ...

For prostate cancer patients with low-volume tumors and metastasis, the median overall survival was 37.13 months. Prostate cancer patients with metastatic disease and low-volume primary tumors appear ...

In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPC; Real‑world evidence showed Pluvicto achieved longer PFS when init ...

Despite a lack of level 1 evidence, metastasis-directed therapy has been increasingly used for the treatment of oligometastatic prostate cancer based on findings from several randomized phase II ...

Many cancers can often be treated successfully when detected early. Surgery, radiation and chemotherapy are all powerful tools to remove or destroy tumors in their original location. However, when ...

The addition of neoadjuvant Lutetium-177 (Lu-177) therapy to metastasis-directed stereotactic body radiation therapy (SBRT) more than doubled progression-free survival (PFS) in men with ...

A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...

A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment intensification can meaningfully improve survival for patients with ...

Excess body weight, as measured by BMI, is associated with improved overall survival (OS) in men with advanced prostate cancer, particularly those with metastatic castration-resistant disease, a ...

CURE highlights prostate cancer advancements from Day One of the 2026 ASCO Genitourinary Cancers Symposium.